Raymond James Financial
NVO

Raymond James Financial’s Novo Nordisk NVO Stock Holding History

Raymond James Financial’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,800
Closed -$794K – 5529
2026
Q1 		$794K Buy
+20,800
New +$986K ﹤0.01% 4029

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Raymond James Financial's NVO Position: Q2 2026 in Review

Raymond James Financial reduced its Novo Nordisk (NVO) stake by 18% in Q2 2026, selling an estimated $26.9M and leaving 2,903,988 shares worth $139M. The position accounts for 0.04% of the portfolio, ranked #429.

Raymond James Financial first reported a position in NVO in Q4 2024 and has held it in 7 quarters since. The position peaked at $405M in Q4 2024. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Raymond James Financial held 2,903,988 shares of Novo Nordisk worth $139M as of Q2 2026.
  • Raymond James Financial sold 627,017 Novo Nordisk shares in Q2 2026, an estimated $26.9M.
  • Novo Nordisk made up 0.04% of Raymond James Financial's portfolio in Q2 2026, its #429 holding.
  • Raymond James Financial first reported a position in Novo Nordisk in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Novo Nordisk position peaked at $405M in Q4 2024.
  • 1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.